Dengue virus (DENV) represents an emerging/re-emerging infectious disease that causes significant human morbidity and mortality. It is estimated that there are 25 to 100 million cases of DENV infection each year and 2.5 billion people are at risk. Children and infants in endemic countries account for the majority of the 25,000 DENV-associated deaths that occur annually. There is currently no commercial vaccine available. We have developed an innovative vaccine platform that has shown in vivo efficacy against lethal flavivirus infection in two independent models (West Nile virus and Yellow Fever virus) and in this application we will expand on this foundation to develop and produce a new tetravalent vaccine against DENV. The critical obstacle faced by current approaches to live attenuated DENV vaccine development is viral interference, a phenomenon in which the host preferentially mounts an immune response to one or two (but not all) of the four DENV serotypes, leaving the vaccinated subject either unprotected or at potentially increased risk for severe disease if exposed to the wrong DENV serotype. To resolve this problem, our approach utilizes previously attenuated DENV vaccine strains (shown to be safe in human subjects) followed by inactivation with our proprietary hydrogen peroxide (H2O2)-based vaccine technology to prepare highly immunogenic formulations with the potential to elicit a balanced immune response to all four DENV serotypes. This vaccine project encompasses many of the key product development goals listed in RFA-AI-11-014 including, lead vaccine candidate optimization;evaluation of safety, toxicity, and immunogenicity;evaluation of efficacy in appropriate challenge models;evaluation of stability at optimal and elevated storage temperatures;and cGMP manufacturing of vaccine material suitable for completing all applicable IND-enabling preclinical studies. The successful completion of these objectives will result in cGMP-grade vaccine material suitable for future initiation of a Phase I clinical trial, a crucial milestone in the advancement of a human vaccine for this important NIAID Category A Priority Pathogen.

Public Health Relevance

In this application, we provide preliminary data demonstrating the antigenicity, immunogenicity, and protective efficacy of a proprietary new H2O2-based vaccine platform that can be used to develop a safe and effective tetravalent dengue virus vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI098723-01
Application #
8267908
Study Section
Special Emphasis Panel (ZAI1-RGK-M (J2))
Program Officer
Cassetti, Cristina
Project Start
2012-05-01
Project End
2017-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
1
Fiscal Year
2012
Total Cost
$1,327,554
Indirect Cost
$252,937
Name
Oregon Health and Science University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Austin, S Kyle; Dowd, Kimberly A (2014) B cell response and mechanisms of antibody protection to West Nile virus. Viruses 6:1015-36
Slifka, Mark K; Amanna, Ian (2014) How advances in immunology provide insight into improving vaccine efficacy. Vaccine 32:2948-57
Amanna, Ian J; Slifka, Mark K (2014) Current trends in West Nile virus vaccine development. Expert Rev Vaccines 13:589-608
Slifka, Mark K; Hammarlund, Erika; Lewis, Matthew W et al. (2013) Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG. Transplantation 95:e59-61
Rowe, Alexander M; Murray, Susan E; Raue, Hans-Peter et al. (2013) A cell-intrinsic requirement for NF-*B-inducing kinase in CD4 and CD8 T cell memory. J Immunol 191:3663-72
Pinto, Amelia K; Richner, Justin M; Poore, Elizabeth A et al. (2013) A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol 87:1926-36